Accessibility helpSkip to navigationSkip to contentSkip to footer

Cookies on FT Sites

We use cookies for a number of reasons, such as keeping FT Sites reliable and secure, personalising content and ads, providing social media features and to analyse how our Sites are used.

Accept & continue
Manage cookies
  • Sign In
  • Subscribe
Open side navigation menuOpen search bar
Financial Times
SubscribeSign InmyFT
  • Home
  • World
    Sections
    • World Home
    • Global Economy
    • UK
    • US
    • China
    • Africa
    • Asia Pacific
    • Emerging Markets
    • Europe
    • War in Ukraine
    • Americas
    • Middle East & North Africa
    • Australia & NZ
    Most Read
    • Donald Trump backs ‘immediate release’ of documents on FBI search of Mar-a-Lago
    • Luxury watch prices plummet on weak Chinese consumer confidence
    • Spain says gas link to wider EU could be ready within months
    • Trump under investigation for possible violation of US Espionage Act
    • Author Salman Rushdie stabbed at event in New York state
  • US
    Sections
    • US Home
    • US Economy
    • US Companies
    • US Politics & Policy
    Most Read
    • Companies
      Sections
      • Companies Home
      • Energy
      • Financials
      • Health
      • Industrials
      • Media
      • Professional Services
      • Retail & Consumer
      • Tech Sector
      • Telecoms
      • Transport
      Most Read
      • Miami becomes the new boom town for corporate lawyers
      • The Qantas chief who brought a new travel disruption term to Australian vernacular
      • Scotch whisky shows surprising strength in global gloom
      • UK energy tax breaks are at odds with cost of living crisis
      • Mark Carney to become chair of Brookfield’s asset management spin-off
    • Tech
    • Markets
      Sections
      • Markets Home
      • Alphaville
      • Markets Data
      • Capital Markets
      • Commodities
      • Currencies
      • Equities
      • Fund Management
      • Trading
      • Moral Money
      • ETF Hub
      • Cryptofinance
      Most Read
      • Live news updates from August 12: Trump under Espionage Act investigation, Salman Rushdie stabbed in western New York
      • Spain says gas link to wider EU could be ready within months
      • Asset managers bet big on crypto despite market rout
      • Glencore cuts ties with Chinese trader over missing $500mn of copper
      • Next financial crisis likely to centre on private markets
    • Climate
    • Opinion
      Sections
      • Opinion Home
      • Columnists
      • The FT View
      • The Big Read
      • Lex
      • Obituaries
      • Letters
      Most Read
      • Mortgage wake-up call for middle classes
      • Next financial crisis likely to centre on private markets
      • Western companies wake up to China risk
      • Russia’s diplomats are now reduced to propagandists
      • Companies are struggling to adjust as consumers go cold on goods
    • Work & Careers
      Sections
      • Work & Careers Home
      • Business School Rankings
      • Business Education
      • Entrepreneurship
      • Recruitment
      • Business Books
      • Business Travel
      Most Read
      • Can a city be redesigned for the new world of work?
      • Brompton’s Will Butler-Adams: ‘People have no idea what goes into a product. That’s not a good thing’
    • Life & Arts
      Sections
      • Life & Arts Home
      • Arts
      • Books
      • Food & Drink
      • FT Magazine
      • House & Home
      • Style
      • Travel
      • FT Globetrotter
      Most Read
      • Is the UK housing market at a turning point?
      • Formula 1’s Toto Wolff: ‘You need to push people out of their comfort zone’
      • How we live now: Afghanistan’s women speak
      • My handwriting is terrible. Should I be worried?
      • The hottest swimwear — influenced by cold water sport
    • HTSI
    MenuSearch
    • Home
    • World
    • US
    • Companies
    • Tech
    • Markets
    • Climate
    • Opinion
    • Work & Careers
    • Life & Arts
    • HTSI
    Financial Times
    SubscribeSign In

    Your guide to a disrupted world

    Start a 4-week trial

    Sanofi SA

    Add to myFT Digest

    Add this topic to your myFT Digest for news straight to your inbox

    • Thursday, 11 August, 2022
      Pharmaceuticals sector
      Pharma groups lose £30bn of value on heartburn drug lawsuit worries

      Companies face thousands of pending personal injury cases linking Zantac to cancer

    • Friday, 24 June, 2022
      Covid-19 vaccines
      Sanofi-GSK Covid vaccine found effective against Omicron

      Pharma companies are hoping to catch up with rivals as they report promising trial results for jab

    • Monday, 13 June, 2022
      Sanofi and GSK report ‘positive’ results from Covid booster

      ‘Next-generation’ jab delivers strong immune response against variants

    • Tuesday, 17 May, 2022
      Electric vehicles
      Unilever and Sanofi pile on pressure over 2035 EU petrol ban

      Cross-section of companies want to ‘ensure laggards don’t delay the market shift’

    • Wednesday, 23 February, 2022
      Covid-19 vaccines
      Sanofi and GSK to seek approval for delayed Covid vaccine

      Drugmakers to apply for protein-based shot to be used as primary and booster jabs

    • Friday, 4 February, 2022
      Sanofi buoyed by blockbuster eczema drug Dupixent

      French pharma group still working on long-delayed Covid vaccine

    • Wednesday, 15 December, 2021
      Sanofi pushes back expected Covid vaccine approval date again

      French pharma group says jab will probably come to market in first quarter of 2022

    • Tuesday, 28 September, 2021
      Covid-19 vaccines
      Sanofi stops development of Covid vaccine based on mRNA technology

      French group says it is too late to market jab and is working on another with GSK using different technique

    • Tuesday, 3 August, 2021
      Lex
      Sanofi/Translate Bio: do recruit the messenger Premium content

      The acquisition is a sign of the French pharma group’s determination to get back on the podium

    • Tuesday, 3 August, 2021
      Sanofi to buy partner Translate Bio for $3.2bn in mRNA push

      French pharma group tries to catch up with rivals that used the technology to create Covid vaccines

    • Thursday, 29 July, 2021
      Sanofi raises annual profit goal

      French group still aims for its Covid-19 jab to be approved by year end

    • Wednesday, 28 July, 2021
      Coronavirus pandemic
      Coronavirus: Biden reveals mandates and calls for incentives to boost vaccinations - as it happened
    • Tuesday, 29 June, 2021
      Sanofi boosts investment in mRNA to keep pace in vaccines

      French group to open a ‘dedicated mRNA centre of excellence’ after falling behind in Covid-19 jab race

    • Tuesday, 15 June, 2021
      Sanofi agrees to inject tens of millions of pounds into UK pension scheme

      Britain’s pension regulator says French drugmaker began talks after threat of enforcement action

    • Monday, 17 May, 2021
      Covid-19 vaccines
      GSK seeks to make up ground in vaccine race

      UK group and France’s Sanofi release trial data of Covid jab showing strong immune response

    • Friday, 12 March, 2021
      Covid-19 vaccines
      Sanofi to start human trials of mRNA vaccine against Covid-19

      French group has fallen behind newcomers despite being one of the biggest jab makers in world

    • Wednesday, 10 March, 2021
      News in-depthFT Film24 min
      Covid-19 and the business of vaccines

      New vaccine producers and mRNA technology are shaking up the market

    • Tuesday, 16 February, 2021
      News in-depthCovid-19 vaccines
      Why the three biggest vaccine makers failed on Covid-19

      GlaxoSmithKline, Merck and Sanofi are left playing catch-up to upstarts with new technology

    • Friday, 5 February, 2021
      European companies
      Sanofi to expand cost-savings push to bolster R&D efforts

      French vaccine maker aims to get a Covid-19 shot to market by the fourth quarter

    • Monday, 11 January, 2021
      Lex
      Sanofi/Kymab: reliance on science Premium content

      Deal is latest in string of acquisitions that have given drugmaker access to new technologies

    • Monday, 11 January, 2021
      Sanofi acquires immunotherapy biotech Kymab

      French group also weighs possibility of manufacturing rival Covid-19 vaccines

    • Friday, 11 December, 2020
      Coronavirus treatment
      Sanofi/GSK delay vaccine rollout and Australia ditches trial

      European partnership hit by dosage issues while Canberra project is derailed by false positive HIV tests

    • Thursday, 29 October, 2020
      Lex
      Sanofi/flu vaccines: lots of shots Premium content

      If vaccination becomes a habit, strong demand would be more than a blip

    • Monday, 17 August, 2020
      LexPharmaceuticals sector
      Sanofi/Principia Biopharma: attraction theory Premium content

      As the French group tries to reduce dependence on some drugs, bolt-on deals make sense

    • Monday, 17 August, 2020
      Sanofi agrees $3.4bn deal for Principia Biopharma

      Chief Paul Hudson’s strategy aims to shift focus to therapies for rarer diseases

    Previous page You are on page 1 Next page

    Useful links

    Support

    View Site TipsHelp CentreContact UsAbout UsAccessibilitymyFT TourCareers

    Legal & Privacy

    Terms & ConditionsPrivacy PolicyCookiesCopyrightSlavery Statement & Policies

    Services

    Share News Tips SecurelyIndividual SubscriptionsGroup SubscriptionsRepublishingExecutive Job SearchAdvertise with the FTFollow the FT on TwitterFT ChannelsSecondary Schools

    Tools

    PortfolioToday's Newspaper (ePaper)Alerts HubBusiness School RankingsEnterprise ToolsNews feedNewslettersCurrency Converter

    Community & Events

    FT CommunityFT LiveFT ForumsFT Board DirectorBoard Director Programme

    More from the FT Group

    Markets data delayed by at least 15 minutes. © THE FINANCIAL TIMES LTD 2022. FT and ‘Financial Times’ are trademarks of The Financial Times Ltd.
    The Financial Times and its journalism are subject to a self-regulation regime under the FT Editorial Code of Practice.
    Financial Times

    International Edition

    Subscribe for full access
    • Switch to UK Edition
    • Top sections
    • Home
    • World
      • Global Economy
      • UK
      • US
      • China
      • Africa
      • Asia Pacific
      • Emerging Markets
      • Europe
      • War in Ukraine
      • Americas
      • Middle East & North Africa
      • Australia & NZ
    • US
      • US Economy
      • US Companies
      • US Politics & Policy
    • Companies
      • Energy
      • Financials
      • Health
      • Industrials
      • Media
      • Professional Services
      • Retail & Consumer
      • Tech Sector
      • Telecoms
      • Transport
    • Tech
    • Markets
      • Alphaville
      • Markets Data
      • Capital Markets
      • Commodities
      • Currencies
      • Equities
      • Fund Management
      • Trading
      • Moral Money
      • ETF Hub
      • Cryptofinance
    • Climate
    • Opinion
      • Columnists
      • The FT View
      • The Big Read
      • Lex
      • Obituaries
      • Letters
    • Work & Careers
      • Business School Rankings
      • Business Education
      • Entrepreneurship
      • Recruitment
      • Business Books
      • Business Travel
    • Life & Arts
      • Arts
      • Books
      • Food & Drink
      • FT Magazine
      • House & Home
      • Style
      • Travel
      • FT Globetrotter
    • Personal Finance
      • Property & Mortgages
      • Investments
      • Pensions
      • Tax
      • Banking & Savings
      • Advice & Comment
      • Next Act
    • HTSI
    • Special Reports
    • FT recommends
    • Lex
    • Alphaville
    • Lunch with the FT
    • FT Globetrotter
    • #techAsia
    • Moral Money
    • FTfm
    • Newsletters
    • Video
    • Podcasts
    • News feed
    • FT Community
      • FT Live
      • FT Forums
      • Board Director Programme
    • myFT
    • Portfolio
    • Today's Newspaper (ePaper)
    • Crossword
    • Our Apps
    • Help Centre
    • Subscribe
    • Sign In